Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ANTX vs SIGA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANTX Captures Overall Composite Edge (37.2 SELL vs 47.5 HOLD), While SIGA Leads 4–1 on Growth & Valuation Pillars

ANTX Overall Winner 6-Pillar Tally: ANTX 1 – 4 SIGA (1 Tie) Matrix Metrics: ANTX 3 – 5 SIGA

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus SIGA at $2.65 (2.5x Forward P/E, -14.2% operating margin).

  • Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY).
  • Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANTX vs SIGA
ANTX NASDAQ Head-to-Head Winner
AN2 Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.22
+5.45% 1D
Market Cap $190.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.75β · 98% Vol
Unified Composite Score
37.2 / 100 SELL
Tech 15.0 Fund 39.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.0 · SMA20: $4.31 · SMA50: $4.52
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $3.02 · SMA50: $3.14

6-Pillar Scorecard Institutional Category Breakdown (ANTX 1 – 4 SIGA)

Columns: Metric · ANTX · SIGA
1. Valuation Multiples SIGA
Forward P/E N/M 2.5x
Trailing P/E N/M N/M
PEG Ratio N/M 3.37x
EV / Revenue N/M 1.4x
2. Growth & Scale ANTX
Revenue Growth (YoY) +0.0% -49.7%
Earnings Growth (YoY) +0.0% -65.3%
TTM Revenue (USD) N/A $52M
Market Cap $190.1M $187.9M
3. Profitability & Quality SIGA
Gross Margin N/A 23.4%
Operating Margin 0.0% -14.2%
Net Profit Margin 0.0% 1.3%
Return on Equity (ROE) -51.3% 0.4%
4. Balance Sheet & Cash Flow SIGA
Cash Generation (TTM) -$30M -$12M
Cash Flow Margin N/A -22.1%
Net Cash / Leverage $1.99 Book/Sh · -51.3% ROE $116M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 134.2% (22nd %ile) 81.4% (8th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat SIGA
OpEx & R&D Intensity N/A 37.6% of Rev ($20M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANTX (3) vs SIGA (5)
Institutional Metric ANTX SIGA Criterion Row Edge
Market Capitalization
Scale
$190.1M $187.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 2.5x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
+0.0% -49.7% Higher Growth ANTX
Operating Margin (TTM)
Profitability
0.0% -14.2% Higher Margin ANTX
Net Profit Margin
Profitability
0.0% 1.3% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
-51.3% 0.4% Higher ROE SIGA
52-Week Range Position
Momentum
68% ($1–$7) 3% ($3–$7) Stronger Trend ANTX
Beta / 30D Volatility
Risk Regime
0.75β · 98% Vol 0.75β · 65% Vol Lower Realized Risk SIGA
Unified Institutional Score
Composite Signal
37.2 / 100 (SELL) 47.5 / 100 (HOLD) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
N/A $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 23.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.37x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$30M ($1.99 Book/Sh · -51.3% ROE) -$12M ($116M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANTX +60.06 pp
ANTX: +45.0% · SIGA: -15.06%
3M Horizon ANTX +2.68 pp
ANTX: -10.15% · SIGA: -12.83%
6M Horizon ANTX +50.49 pp
ANTX: +6.75% · SIGA: -43.74%
1Y Horizon ANTX +421.68 pp
ANTX: +366.07% · SIGA: -55.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANTX vs SIGA. Trailing 12-month operating profitability (ANTX 0.0% vs SIGA -14.2%) and valuation multiples (ANTX N/M vs SIGA 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.

ANTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-51.3% · N/M
SIGA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$52M
Gross Margin23.4%
Op. Margin-14.2%
ROE / Fwd P/E0.4% · 2.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANTX CONSOLIDATION
177d in phase · OBV NEUTRAL
Current IV 134.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ANTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $190.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published

Investor FAQ ANTX vs SIGA Key Questions & Quantitative Answers

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus SIGA at $2.65 (2.5x Forward P/E, -14.2% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY). Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANTX leads the Growth & Scale pillar: ANTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SIGA at -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin). On trailing 12-month operating scale, ANTX generates N/A in USD-normalized revenue versus $52M for SIGA. In operating R&D and SG&A reinvestment, ANTX deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($20M) (0 disclosures) for SIGA.

SIGA screens cheaper on headline valuation multiples. ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANTX (-51.3% ROE) versus SIGA (0.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ANTX carries 134.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 98% Vol realized risk). By comparison, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.